Author

Hee Sun Cho

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Blocking the gut-liver IgA axis attenuates macrophage-mediated inflammation and injury in alcohol-associated liver disease.

BACKGROUND Alcohol-associated liver disease (ALD) is a major cause of morbidity, yet therapies for severe inflammation remain limited. OBJECTIVE We examined whether circulating and hepatic immunoglobulin A (IgA) and hepatic myeloid-cell IgA binding are associated with interleukin-1 beta (IL-1β)-linked inflammation an...

Min Gu Kim, K. Tak, D. Seo et al. · Gut · 0 citations

Meta-analysis Open access Sep 2026

Real-world outcomes of atezolizumab–bevacizumab and durvalumab–tremelimumab in unresectable hepatocellular carcinoma: a systematic review with covariate-adjusted meta-regression and exploratory machine learning analysis

Background/purpose Atezolizumab–bevacizumab (AB) and durvalumab–tremelimumab (DT) are standard first-line therapies for unresectable hepatocellular carcinoma (uHCC), but their comparative effectiveness remains uncertain. Methods We included 76 observational reports comprising 10,243 patients. Report-level median surviv...

Jongin Lee, K. Tak, Hee Sun Cho et al. · Frontiers in Immunology · 0 citations

Review Aug 2026

Comparison of Second-line Hepatic Arterial Infusion Chemotherapy and Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma.

In patients with advanced HCC, after AB failure, second-line HAIC yielded higher response rates and longer PFS than TKIs, and after IPTW, HAIC remained associated with longer PFS than TKIs.

Jae-Sung Yoo, K. Tak, Hee Sun Cho et al. · Radiology · 0 citations